10140 related articles for article (PubMed ID: 15605765)
1. [The factors of disease-free survival in patients with nodal metastases of cutaneous melanoma].
Mikhnin AE; Barchuk AS
Vopr Onkol; 2004; 50(4):426-9. PubMed ID: 15605765
[TBL] [Abstract][Full Text] [Related]
2. [Survival analysis in patients with cutaneous malignant melanoma].
Radović-Kovacević V; Pekmezović T; Adanja B; Jarebinski M; Marinković J; Tomin R
Srp Arh Celok Lek; 1997; 125(5-6):132-7. PubMed ID: 9265233
[TBL] [Abstract][Full Text] [Related]
3. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.
Niakosari F; Kahn HJ; McCready D; Ghazarian D; Rotstein LE; Marks A; Kiss A; From L
Arch Dermatol; 2008 Apr; 144(4):462-7. PubMed ID: 18427039
[TBL] [Abstract][Full Text] [Related]
4. Independent prognostic importance of vascular invasion in nodular melanomas.
Straume O; Akslen LA
Cancer; 1996 Sep; 78(6):1211-9. PubMed ID: 8826942
[TBL] [Abstract][Full Text] [Related]
5. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma.
Nowecki ZI; Rutkowski P; Nasierowska-Guttmejer A; Ruka W
Ann Surg Oncol; 2006 Dec; 13(12):1655-63. PubMed ID: 17016755
[TBL] [Abstract][Full Text] [Related]
6. The survival benefit to patients with positive sentinel node melanoma after completion lymph node dissection may be limited to the subgroup with a primary lesion Breslow thickness greater than 1.0 and less than or equal to 4 mm (pT2-pT3).
Nowecki ZI; Rutkowski P; Michej W
Ann Surg Oncol; 2008 Aug; 15(8):2223-34. PubMed ID: 18506535
[TBL] [Abstract][Full Text] [Related]
7. Natural history of melanoma in 773 patients with tumor-negative sentinel lymph nodes.
Zogakis TG; Essner R; Wang HJ; Foshag LJ; Morton DL
Ann Surg Oncol; 2007 May; 14(5):1604-11. PubMed ID: 17333418
[TBL] [Abstract][Full Text] [Related]
8. The prognostic impact of the extent of lymph node dissection in patients with stage III melanoma.
Galliot-Repkat C; Cailliod R; Trost O; Danino A; Collet E; Lambert D; Vabres P; Dalac S
Eur J Surg Oncol; 2006 Sep; 32(7):790-4. PubMed ID: 16822643
[TBL] [Abstract][Full Text] [Related]
9. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.
Mandalà M; Imberti GL; Piazzalunga D; Belfiglio M; Labianca R; Barberis M; Marchesi L; Poletti P; Bonomi L; Novellino L; Di Biagio K; Milesi A; Guerra U; Tondini C
Eur J Cancer; 2009 Sep; 45(14):2537-45. PubMed ID: 19553103
[TBL] [Abstract][Full Text] [Related]
10. Isolated tumor cells in the sentinel node affect long-term prognosis of patients with melanoma.
Scheri RP; Essner R; Turner RR; Ye X; Morton DL
Ann Surg Oncol; 2007 Oct; 14(10):2861-6. PubMed ID: 17882497
[TBL] [Abstract][Full Text] [Related]
11. [Sentinel lymph node biopsy for melanoma: prognostic value and disadvantages in 300 patients].
de Vries M; Jager PL; Suurmeijer AJ; Plukker JT; van Ginkel RJ; Hoekstra HJ
Ned Tijdschr Geneeskd; 2005 Aug; 149(33):1845-51. PubMed ID: 16128183
[TBL] [Abstract][Full Text] [Related]
12. Sentinel node status in melanoma patients is not predictive for overall survival upon multivariate analysis.
Roka F; Kittler H; Cauzig P; Hoeller C; Hinterhuber G; Wolff K; Pehamberger H; Diem E
Br J Cancer; 2005 Feb; 92(4):662-7. PubMed ID: 15700039
[TBL] [Abstract][Full Text] [Related]
13. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.
Taylor RC; Patel A; Panageas KS; Busam KJ; Brady MS
J Clin Oncol; 2007 Mar; 25(7):869-75. PubMed ID: 17327608
[TBL] [Abstract][Full Text] [Related]
14. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study.
Barnhill RL; Fine JA; Roush GC; Berwick M
Cancer; 1996 Aug; 78(3):427-32. PubMed ID: 8697387
[TBL] [Abstract][Full Text] [Related]
15. Factors predictive of nonsentinel lymph node involvement and clinical outcome in melanoma patients with metastatic sentinel lymph node.
Rossi CR; De Salvo GL; Bonandini E; Mocellin S; Foletto M; Pasquali S; Pilati P; Lise M; Nitti D; Rizzo E; Montesco MC
Ann Surg Oncol; 2008 Apr; 15(4):1202-10. PubMed ID: 18165880
[TBL] [Abstract][Full Text] [Related]
16. Effect of multiple-nodal basin drainage on cutaneous melanoma.
Federico AC; Chagpar AB; Ross MI; Martin RC; Noyes RD; Goydos JS; Beitsch PD; Urist MM; Ariyan S; Sussman JJ; McMasters KM; Scoggins CR;
Arch Surg; 2008 Jul; 143(7):632-7; discussion 637-8. PubMed ID: 18645103
[TBL] [Abstract][Full Text] [Related]
17. Pelvic lymph node dissection is beneficial in subsets of patients with node-positive melanoma.
Badgwell B; Xing Y; Gershenwald JE; Lee JE; Mansfield PF; Ross MI; Cormier JN
Ann Surg Oncol; 2007 Oct; 14(10):2867-75. PubMed ID: 17671814
[TBL] [Abstract][Full Text] [Related]
18. Combined-modality therapy for patients with regional nodal metastases from melanoma.
Ballo MT; Ross MI; Cormier JN; Myers JN; Lee JE; Gershenwald JE; Hwu P; Zagars GK
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):106-13. PubMed ID: 16182463
[TBL] [Abstract][Full Text] [Related]
19. N-ratio: a novel independent prognostic factor for patients with stage-III cutaneous melanoma.
Rossi CR; Mocellin S; Pasquali S; Pilati P; Nitti D
Ann Surg Oncol; 2008 Jan; 15(1):310-5. PubMed ID: 17987346
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma.
Clemente CG; Mihm MC; Bufalino R; Zurrida S; Collini P; Cascinelli N
Cancer; 1996 Apr; 77(7):1303-10. PubMed ID: 8608507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
